Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Stock Position Increased by BML Capital Management LLC

BML Capital Management LLC grew its stake in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 13.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 5,462,079 shares of the company's stock after acquiring an additional 662,079 shares during the quarter. Atea Pharmaceuticals comprises about 12.6% of BML Capital Management LLC's portfolio, making the stock its 3rd biggest holding. BML Capital Management LLC owned approximately 6.55% of Atea Pharmaceuticals worth $16,659,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently modified their holdings of the stock. Stonepine Capital Management LLC lifted its position in shares of Atea Pharmaceuticals by 128.7% during the 3rd quarter. Stonepine Capital Management LLC now owns 1,720,000 shares of the company's stock valued at $5,160,000 after acquiring an additional 967,912 shares during the period. Sectoral Asset Management Inc. raised its holdings in shares of Atea Pharmaceuticals by 19.7% during the 3rd quarter. Sectoral Asset Management Inc. now owns 600,461 shares of the company's stock worth $1,801,000 after buying an additional 98,924 shares in the last quarter. Newtyn Management LLC raised its holdings in shares of Atea Pharmaceuticals by 348.4% during the 3rd quarter. Newtyn Management LLC now owns 400,000 shares of the company's stock worth $1,200,000 after buying an additional 310,803 shares in the last quarter. GSA Capital Partners LLP raised its holdings in shares of Atea Pharmaceuticals by 41.9% during the 3rd quarter. GSA Capital Partners LLP now owns 278,286 shares of the company's stock worth $835,000 after buying an additional 82,208 shares in the last quarter. Finally, CM Management LLC raised its holdings in shares of Atea Pharmaceuticals by 10.0% during the 3rd quarter. CM Management LLC now owns 275,000 shares of the company's stock worth $825,000 after buying an additional 25,000 shares in the last quarter. 86.67% of the stock is currently owned by institutional investors.

Atea Pharmaceuticals Stock Performance

Shares of Atea Pharmaceuticals stock traded down $0.03 during trading on Wednesday, reaching $3.70. 196,517 shares of the company's stock were exchanged, compared to its average volume of 426,177. Atea Pharmaceuticals, Inc. has a 1-year low of $2.77 and a 1-year high of $5.19. The company has a market cap of $311.43 million, a P/E ratio of -2.26 and a beta of 0.16. The firm's 50-day moving average price is $3.98 and its 200 day moving average price is $3.52.

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.03). As a group, equities research analysts predict that Atea Pharmaceuticals, Inc. will post -2.76 EPS for the current year.

Insiders Place Their Bets

In other Atea Pharmaceuticals news, insider Andrea Corcoran sold 15,843 shares of the company's stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $3.84, for a total value of $60,837.12. Following the completion of the transaction, the insider now owns 670,208 shares of the company's stock, valued at approximately $2,573,598.72. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Atea Pharmaceuticals news, CAO Wayne Foster sold 12,477 shares of the company's stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $3.84, for a total value of $47,911.68. Following the sale, the chief accounting officer now owns 20,857 shares in the company, valued at approximately $80,090.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Andrea Corcoran sold 15,843 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $3.84, for a total value of $60,837.12. Following the completion of the sale, the insider now directly owns 670,208 shares of the company's stock, valued at approximately $2,573,598.72. The disclosure for this sale can be found here. Insiders sold a total of 85,230 shares of company stock valued at $327,852 in the last 90 days. Corporate insiders own 14.50% of the company's stock.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.